Possible pentostatin-induced symptomatic hyponatremia

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 164-169

  Bruno, Jeffrey J ^a   Canada, Todd W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hyponatremia; Lymphoma; Pentostatin; SIADH; Syndrome of inappropriate antidiuretic hormone

Indexed keywords

AZITHROMYCIN; BICARBONATE; CARVEDILOL; CASPOFUNGIN; CEFEPIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; FUROSEMIDE; GEMCITABINE; METHOTREXATE; MOXIFLOXACIN; PANTOPRAZOLE; PENTOSTATIN; PREDNISOLONE; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SODIUM; SODIUM CHLORIDE; VALACICLOVIR; VINCRISTINE; VORICONAZOLE;

ADULT; ANURIA; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DERMATOMYCOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTENSIVE CARE UNIT; LYMPHOMA; MALE; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OXYGEN THERAPY; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; SERUM OSMOLALITY; SLEEP APNEA SYNDROME; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; SURVIVAL; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINE OSMOLALITY; VIRUS INFECTION;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; HYPONATREMIA; LYMPHOMA, T-CELL; MALE; PENTOSTATIN;

EID: 33846065163     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.164     Document Type: Article

References (18)

1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581-9.
2. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003;37(11):1694-702.
3. Han DS, Cho BS. Therapeutic approach to hyponatremia. Nephron 2002;92(suppl 1):9-13.
4. Moore K, Thompson C, Trainer P. Disorders of water balance. Clin Med 2003;3(1):28-33.
5. Al-Salman J, Kemp D, Randall D. Hyponatremia. West J Med 2002;176(3):173-6.
6. SuperGen Inc. Nipent (pentostatin) package insert. Dublin, CA; 2002.
7. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9(4):565-71.
8. Monfardini S, Sorio R, Cavalli F, et al. Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC early clinical trials group. Oncology 1996;53(2):163-8.
9. Greiner D, Olsen EA, Petroni G. Pentostatin (2′- deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36(6 pt 1):950-5.
10. Foss FM. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. Semin Oncol 2000;27(2 suppl 5):58-63.
11. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell-lymphoma. Oncology (Williston Park) 2000;14(6 suppl 2):37-40.
12. Kurzrock R. Therapy of T-cell lymphomas with pentostatin. Ann N Y Acad Sci 2001;941:200-5.
13. Dang NH, Hagemeister FB, Duvic M, et al. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 2003;10(5):1513-18.
14. Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. Can Med Assoc J 2002;166(8):1056-62.
15. Yeates KE, Singer M, Morton AR. Salt and water: a simple approach to hyponatremia. Can Med Assoc J 2004;170(3): 365-9.
16. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35(11): 1495-9.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
18. Rose BD, Post TW, eds. Effects of hormones on renal function. In: Clinical physiology of acid-base and electrolyte disorders, 5th ed. New York: McGraw-Hill, 2001:163-238.